Building on clinical trial and laboratory research insights from the past decade, the ITN has focused and deliberate strategies to achieving tolerance in each disease area. The research supported by the ITN has unlocked new therapeutic approaches and discovered new biomarkers that promise to change the way physicians treat patients. Explore ITN clinical trials below by using a search term or by sorting the specific trial categories. If you have questions or want more information about ITN clinical trials, contact us.
Principal Investigator:
Samia Khoury | Harvard University | Boston, MA
Multiple sclerosis (MS) is an autoimmune disorder. In this disease, the body's immune system attacks and destroys the cells that cover and protect nerves. This study will test the safety of a new drug called RG2077 that is designed to treat MS. The study will not determine whether RG2077 is effective in treating MS, only whether it is safe to use in patients with MS.
Category:
Autoimmune Disease
|
Specific Category:
Multiple Sclerosis
|
Status:
Complete
Learn more:
(
ITN005CT
|
)
Principal Investigator:
James Shapiro | University of Alberta | Edmonton, AB
This was a multicenter clinical trial of the Edmonton protocol for islet transplantation.
Category:
Transplantation
|
Specific Category:
Islet Transplantation
|
Status:
Complete
Learn more:
(
ITN001AD
|
)
Principal Investigator:
Peter Creticos | Johns Hopkins University | Baltimore, MD
This study will evaluate the effectiveness of a six-week course of a DNA-based vaccine for seasonal allergic rhinitis, also known as hayfever.
Category:
Allergy & Asthma
|
Specific Category:
Hayfever
|
Status:
Complete
Learn more:
No items found.
